Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy Journal Article
| Authors: | Kollmeier, M. A.; Katz, M. S.; Mak, K.; Yamada, Y.; Feder, D. J.; Zhang, Z.; Jia, X.; Shi, W.; Zelefsky, M. J. |
| Article Title: | Improved biochemical outcomes with statin use in patients with high-risk localized prostate cancer treated with radiotherapy |
| Abstract: | Purpose: To investigate the association between 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) and biochemical and survival outcomes after high-dose radiotherapy (RT) for prostate cancer. Methods and Materials: A total of 1711 men with clinical stage T1-T3 prostate cancer were treated with conformal RT to a median dose of 81 Gy during 1995-2007. Preradiotherapy medication data were available for 1681 patients. Three hundred eighty-two patients (23%) were taking a statin medication at diagnosis and throughout RT. Nine hundred forty-seven patients received a short-course of neoadjuvant and concurrent androgen-deprivation therapy (ADT) with RT. The median follow-up was 5.9 years. Results: The 5- and 8-year PSA relapse-free survival (PRFS) rates for statin patients were 89% and 80%, compared with 83% and 74% for those not taking statins (p = 0.002). In a multivariate analysis, statin use (hazard ratio [HR] 0.69, p = 0.03), National Comprehensive Cancer Network (NCCN) low-risk group, and ADT use were associated with improved PRFS. Only high-risk patients in the statin group demonstrated improvement in PRFS (HR 0.52, p = 0.02). Across all groups, statin use was not associated with improved distant metastasis-free survival (DMFS) (p = 0.51). On multivariate analysis, lower NCCN risk group (p = 0.01) and ADT use (p = 0.005) predicted improved DMFS. Conclusions: Statin use during high-dose RT for clinically localized prostate cancer was associated with a significant improvement in PRFS in high-risk patients. These data suggest that statins have anticancer activity and possibly provide radiosensitization when used in conjunction with RT in the treatment of prostate cancer. Copyright © 2011 Elsevier Inc. |
| Keywords: | radiotherapy; prostate cancer; biochemical outcome; hmg coa reductase inhibitors; statin |
| Journal Title: | International Journal of Radiation Oncology, Biology, Physics |
| Volume: | 79 |
| Issue: | 3 |
| ISSN: | 0360-3016 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2011-03-01 |
| Start Page: | 713 |
| End Page: | 718 |
| Language: | English |
| DOI: | 10.1016/j.ijrobp.2009.12.006 |
| PROVIDER: | scopus |
| PUBMED: | 20452139 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 4 March 2011" - "CODEN: IOBPD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work